Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma. It serves hospitals and other medical care locations through its distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
Australian Market Performance
7D7 Days: -0.2%
3M3 Months: 5.6%
1Y1 Year: 8.6%
YTDYear to Date: 5.1%
In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.2%. Meanwhile, the market is actually up 8.6% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.